Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2026 07:06 ET | Source: Microchip Technology Inc.

Microchip Technology Earns IEC 62443-4-1 ML2 Industrial Automation and Control System Certification

Customers need partners who can demonstrate security, not just claim it: IEC 62443 certification proves Microchip's secure development maturity.
April 02, 2026 07:01 ET | Source: Research and Markets

Low-Grade Glioma Market Trends and Investment Opportunities Through 2030 & 2035: Regional Insights for Trametinib, Dabrafenib, Ivosidenib, and Mirdametinib

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Low-Grade Glioma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global low-grade glioma market is experiencing a...
April 02, 2026 07:00 ET | Source: Wix.com, Ltd.

Wix Announces Preliminary Results of Modified Dutch Auction Tender Offer

Wix announces the preliminary results of its “modified Dutch Auction” tender.
April 02, 2026 07:00 ET | Source: MAX Power Mining Corp

MAX Power Advances Basin-Scale Discovery Potential with Multi-Zone Natural Hydrogen and Helium Intervals at Bracken

Bracken Well at Grasslands Project, 325 km southwest of Lawson Discovery, is successfully cased after being drilled to a total depth of 2,600 meters Mixed gas interval with Helium and Natural Hydrogen...
April 02, 2026 07:00 ET | Source: Neutrolis, Inc.

Neutrolis Announces Positive First-in-Human Phase 1a Results from LIBERATE-I Trial of NTR-1011, a First-in-Class DNASE1L3 Fusion Protein

NTR-1011 demonstrated a favorable safety, tolerability, and immunogenicity profile across multiple dose levels of intravenous (IV) and subcutaneous (SC) administrationsNTR-1011 displayed a predictable...
April 02, 2026 07:00 ET | Source: Adagene Inc.

Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response

Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement...
April 02, 2026 07:00 ET | Source: Abcourt Mines Inc.

Abcourt obtient l’approbation de la TSXV pour mettre en place une offre publique de rachat dans le cours normal des activités (OPRCNA)

ROUYN-NORANDA, Québec, 02 avr. 2026 (GLOBE NEWSWIRE) -- Mines Abcourt Inc. (« Abcourt » ou la « société ») (TSX Venture: ABI) (OTCQB: ABMBF) est heureuse d’annoncer que la Bourse de croissance...
April 02, 2026 07:00 ET | Source: Abcourt Mines Inc.

Abcourt Mines Receives TSXV Approval to Implement a Normal Course Issuer Bid (NCIB)

ROUYN-NORANDA, Quebec, April 02, 2026 (GLOBE NEWSWIRE) -- Abcourt Mines Inc. ("Abcourt" or the "Company") (TSX Venture: ABI) (OTCQB: ABMBF) is pleased to announce that the TSX Venture Exchange...
April 02, 2026 07:00 ET | Source: Liberty Gold Corp.

Liberty Gold Completes Sale of the Gage Project

VANCOUVER, British Columbia, April 02, 2026 (GLOBE NEWSWIRE) -- Liberty Gold Corp. (TSX: LGD; OTCQX: LGDTF) (“Liberty Gold” or the “Company”) announces that it has completed the divestiture of the...
April 02, 2026 06:48 ET | Source: Research and Markets

Medulloblastoma Drugs Market Analysis and Growth Forecast 2026-2030 & 2035 by Drug Candidate, Product, Route of Administration, Distribution Channel, End-user and Region

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Medulloblastoma Drug Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights, covering...